167 related articles for article (PubMed ID: 22959026)
1. Emerging strategies for targeting cell adhesion in multiple myeloma.
Nair RR; Gebhard AW; Emmons MF; Hazlehurst LA
Adv Pharmacol; 2012; 65():143-89. PubMed ID: 22959026
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
Anderson KC
Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
[TBL] [Abstract][Full Text] [Related]
3. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
4. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.
Siegel DS
Semin Hematol; 2012 Jul; 49 Suppl 1():S3-15. PubMed ID: 22727390
[TBL] [Abstract][Full Text] [Related]
5. Targeting multiple myeloma cells and their bone marrow microenvironment.
Pagnucco G; Cardinale G; Gervasi F
Ann N Y Acad Sci; 2004 Dec; 1028():390-9. PubMed ID: 15650264
[TBL] [Abstract][Full Text] [Related]
6. The evolution and impact of therapy in multiple myeloma.
Laubach JP; Richardson PG; Anderson KC
Med Oncol; 2010 Jun; 27 Suppl 1():S1-6. PubMed ID: 20169425
[TBL] [Abstract][Full Text] [Related]
7. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
9. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Podar K; Richardson PG; Chauhan D; Anderson KC
Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
Yasui H; Hideshima T; Richardson PG; Anderson KC
Br J Haematol; 2006 Feb; 132(4):385-97. PubMed ID: 16412014
[TBL] [Abstract][Full Text] [Related]
11. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Corre J; Labat E; Espagnolle N; Hébraud B; Avet-Loiseau H; Roussel M; Huynh A; Gadelorge M; Cordelier P; Klein B; Moreau P; Facon T; Fournié JJ; Attal M; Bourin P
Cancer Res; 2012 Mar; 72(6):1395-406. PubMed ID: 22301101
[TBL] [Abstract][Full Text] [Related]
12. Moving disease biology from the lab to the clinic.
Anderson KC
Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of novel therapeutic targets for multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Anderson KC
J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
[TBL] [Abstract][Full Text] [Related]
15. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide in multiple myeloma.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of novel combinations for induction therapy in multiple myeloma.
Voorhees PM; Orlowski RZ
Clin Lymphoma Myeloma; 2006 Jul; 7(1):33-41. PubMed ID: 16879768
[TBL] [Abstract][Full Text] [Related]
18. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.
Menu E; van Valckenborgh E; van Camp B; Vanderkerken K
Arch Physiol Biochem; 2009 May; 115(2):49-57. PubMed ID: 19234898
[TBL] [Abstract][Full Text] [Related]
19. The malignant clone and the bone-marrow environment.
Podar K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
Best Pract Res Clin Haematol; 2007 Dec; 20(4):597-612. PubMed ID: 18070708
[TBL] [Abstract][Full Text] [Related]
20. Clinical updates and nursing considerations for patients with multiple myeloma.
Faiman B
Clin J Oncol Nurs; 2007 Dec; 11(6):831-40. PubMed ID: 18063542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
